GILEAD SCIENCES, INC.
GILEAD SCIENCES, INC.
Insider Sentiment (TTM):
Last Purchase:-Last Sale:2026-06-15Shares Purchased (TTM):0Shares Sold (TTM):526,231
Institutional Sentiment:
As of:2026-03-31Institutional Shares Owned:973,233,293Shares Outstanding:1,242,000,000Institutional Ownership Pct.:78.36%
Earnings Market Reaction:
Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 3,179 | 7,628 | 7,564 | 7,330 | 5,144 | 7,926 | 9,991 | 5,037 | 2,772 | 4,718 | 6,085 | 5,705 | |||||
Marketable Securities Current | 0 | 15 | 68 | 19 | 69 | - | 0 | 0 | 0 | 0 | 1,179 | 1,159 | |||||
Accounts Receivable Net Current | 5,055 | 4,741 | 4,913 | 5,095 | 4,781 | 4,388 | 4,420 | 4,587 | 4,663 | 4,669 | 4,660 | 4,790 | |||||
Inventory Net | 1,953 | 1,914 | 1,774 | 1,785 | 1,825 | 1,759 | 1,710 | 1,869 | 2,026 | 1,853 | 1,787 | 1,663 | |||||
Prepaid Expense And Other Assets Current | 3,759 | 4,342 | 4,024 | 3,645 | 2,899 | 2,828 | 3,052 | 3,287 | 2,856 | 2,800 | 2,374 | 2,662 | |||||
Assets Current | 13,945 | 18,641 | 18,342 | 17,874 | 14,718 | 16,901 | 19,173 | 14,779 | 12,317 | 14,041 | 16,085 | 15,980 | |||||
Property Plant And Equipment Net | 5,833 | 5,638 | 5,606 | 5,500 | 5,459 | 5,421 | 5,414 | 5,391 | 5,346 | 5,321 | 5,317 | 5,572 | |||||
Marketable Securities Noncurrent | 0 | 983 | 2,974 | 2,005 | 1,913 | - | 0 | 0 | 0 | 0 | 1,163 | 1,156 | |||||
Intangible Assets Net Excluding Goodwill | 14,032 | 16,382 | 16,978 | 17,970 | 18,566 | 19,355 | 19,948 | 20,546 | 22,832 | 23,428 | 26,454 | 27,152 | |||||
Goodwill | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | |||||
Deferred Income Tax Assets Net | 2,487 | 1,767 | 1,964 | 1,998 | 2,721 | 2,572 | 2,378 | - | - | - | - | - | |||||
Other Assets Noncurrent | 4,751 | 4,554 | 4,845 | 4,873 | 4,031 | 3,871 | 3,769 | 5,494 | 4,770 | 5,188 | 4,792 | 4,200 | |||||
Assets | 49,362 | 56,278 | 59,023 | 58,533 | 55,721 | 56,434 | 58,995 | 54,525 | 53,579 | 56,292 | 62,125 | 62,373 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 674 | 645 | 715 | 808 | 582 | 737 | 833 | 903 | 537 | 622 | 550 | 586 | |||||
Debt Current | 2,414 | 1,313 | 2,807 | 2,806 | 2,806 | 2,806 | 1,815 | 1,812 | 1,810 | 3,667 | 1,798 | 1,793 | |||||
Other Liabilities Current | 3,699 | 3,399 | 3,953 | 3,752 | 3,586 | 4,615 | 5,464 | 4,896 | 4,510 | 4,464 | 5,130 | 5,852 | |||||
Liabilities Current | 11,020 | 9,476 | 11,813 | 12,298 | 11,189 | 12,344 | 12,004 | 11,725 | 10,781 | 13,015 | 11,280 | 11,945 | |||||
Long Term Debt Noncurrent | 23,832 | 20,861 | 22,129 | 22,135 | 22,140 | 22,146 | 24,896 | 21,437 | 21,540 | 21,527 | 23,189 | 23,189 | |||||
Accrued Income Taxes Noncurrent | 943 | 918 | 896 | 866 | 859 | 819 | 830 | 782 | 738 | 1,967 | 2,039 | 2,088 | |||||
Deferred Income Tax Liabilities Net | 333 | 392 | 402 | 597 | 652 | 709 | 724 | 794 | 907 | 933 | 1,588 | 1,984 | |||||
Other Liabilities Noncurrent | 1,490 | 1,200 | 1,165 | 1,182 | 1,290 | 1,337 | 1,295 | 1,396 | 1,418 | 1,395 | 1,280 | 924 | |||||
Stockholders Equity Inclu… | |||||||||||||||||
Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Additional Paid In Capital | 9,532 | 9,305 | 8,932 | 8,678 | 8,367 | 8,138 | 7,700 | 7,327 | 7,022 | 6,813 | 6,500 | 6,279 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 95 | 78 | 39 | 36 | -18 | 92 | 132 | 73 | 93 | 69 | 28 | 31 | |||||
Retained Earnings Accumulated Deficit | 2,200 | 14,131 | 13,730 | 12,825 | 11,325 | 10,931 | 11,497 | 11,073 | 11,165 | 10,656 | 16,304 | 16,002 | |||||
Stockholders Equity | 11,744 | 23,431 | 22,703 | 21,540 | 19,590 | 19,078 | 19,330 | 18,475 | 18,281 | 17,455 | 22,749 | 22,242 | |||||
Minority Interest | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -72 | |||||
Liabilities And Stockholders Equity | 49,362 | 56,278 | 59,023 | 58,533 | 55,721 | 56,434 | 58,995 | 54,525 | 53,579 | 56,292 | 62,125 | 62,373 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | |||||
Common Stock Shares Issued | 1,241 | 1,242 | 1,241 | 1,242 | 1,242 | 1,245 | 1,246 | 1,246 | 1,246 | 1,246 | 1,246 | 1,247 | |||||
Shares Outstanding | 1,241 | 1,242 | 1,241 | 1,242 | 1,242 | 1,245 | 1,246 | 1,246 | 1,246 | 1,246 | 1,246 | 1,247 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
0/5
Search a metric to start building a table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
0/1
Search a metric to start building a visual
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.28% | -3.98% | -2.91% | - | - | - | - | - | - | - | - | - |
| 2025 | 11.30% | 12.70% | 18.33% | 2.44% | 2.36% | 10.43% | 5.89% | 5.62% | 15.14% | -6.54% | -6.24% | -11.73% |
| 2024 | -1.00% | 6.98% | 20.08% | 4.51% | 11.64% | 18.84% | -2.35% | -2.30% | 3.89% | -5.67% | -7.91% | -9.70% |
| 2023 | - | - | - | - | - | - | -3.67% | 1.41% | -0.45% | 1.22% | -6.50% | -9.40% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 1.27 | 1.97 | 1.55 | 1.45 | 1.32 | 1.37 | 1.60 | 1.26 | 1.14 | 1.08 | 1.43 | 1.34 | |||||
| Quick Ratio | 0.75 | 1.31 | 1.06 | 1.01 | 0.89 | 1.00 | 1.20 | 0.82 | 0.69 | 0.72 | 1.06 | 0.98 | |||||
| Working Capital | 2.93B | 9.17B | 6.53B | 5.58B | 3.53B | 4.56B | 7.17B | 3.05B | 1.54B | 1.03B | 4.81B | 4.04B | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.94 | 0.40 | 0.52 | 0.57 | 0.57 | 0.65 | 0.62 | 0.63 | 0.59 | 0.75 | 0.50 | 0.54 | |||||
| Interest Coverage TTM | -2.50 | 10.33 | 9.79 | 10.30 | 8.05 | 8.36 | 1.70 | 0.57 | 1.78 | 1.11 | 5.42 | 9.00 | |||||
| Debt Ratio | 0.22 | 0.17 | 0.20 | 0.21 | 0.20 | 0.22 | 0.20 | 0.22 | 0.20 | 0.23 | 0.18 | 0.19 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.58 | 0.53 | 0.50 | 0.51 | 0.53 | 0.51 | 0.47 | 0.48 | 0.48 | 0.46 | 0.43 | 0.44 | |||||
| Days Sales Outstanding TTM | 58.94 | 56.03 | 57.85 | 60.75 | 59.71 | 57.52 | 57.63 | 60.47 | 58.36 | 58.71 | 63.51 | 60.92 | |||||
| Receivables Turnover TTM | 6.19 | 6.51 | 6.31 | 6.01 | 6.11 | 6.35 | 6.33 | 6.04 | 6.25 | 6.22 | 5.75 | 5.99 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -2.61 | 7.35 | 6.78 | 6.47 | 5.03 | 4.74 | 0.38 | 0.11 | 0.84 | 0.39 | 4.50 | 4.65 | |||||
| Free Cash Flow Per Share TTM | 10.41 | 8.24 | 7.60 | 7.37 | 7.53 | 7.90 | 8.26 | 7.56 | 5.53 | 6.34 | 5.95 | 6.29 | |||||
| Dividend Per Share TTM | 3.27 | 3.25 | 3.22 | 3.20 | 3.18 | 3.16 | 3.14 | 3.12 | 3.09 | 3.07 | 3.05 | 3.03 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 79.59% | 79.35% | 78.83% | 78.72% | 78.53% | 78.29% | 78.26% | 76.11% | 75.72% | 75.78% | 76.04% | 78.81% | |||||
| Operating Profit Margin TTM | -8.20% | 34.88% | 34.04% | 36.06% | 27.89% | 28.61% | 5.78% | 2.90% | 9.20% | 5.75% | 28.05% | 30.16% | |||||
| Net Profit Margin TTM | -10.64% | 30.99% | 28.90% | 27.88% | 21.87% | 20.76% | 1.67% | 0.48% | 3.79% | 1.77% | 20.89% | 21.32% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | 5.52% | 3.48% | 2.40% | 2.78% | 3.81% | 4.68% | 6.04% | 3.31% | 1.54% | 1.51% | -0.60% | 0.94% | |||||
| Net Income Growth (1Y) | -151.34% | 54.50% | 1,672.92% | 5,907.41% | 498.77% | 1,129.90% | -91.53% | -97.69% | -80.69% | -91.27% | 24.07% | 76.15% | |||||
| EPS Growth (1Y) | -151.42% | 55.00% | 1,677.19% | 5,926.74% | 499.73% | 1,130.88% | -91.52% | -97.69% | -80.66% | -91.27% | 24.77% | 77.13% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -48.47 | 18.66 | 17.72 | 16.70 | 21.32 | 22.65 | 230.61 | 738.02 | 76.64 | 175.66 | 16.48 | 14.65 | |||||
| P/B TTM | 13.37 | 7.34 | 6.67 | 6.29 | 6.87 | 7.08 | 5.75 | 5.39 | 4.42 | 4.88 | 4.10 | 3.85 | |||||
| P/S TTM | 5.16 | 5.78 | 5.12 | 4.66 | 4.66 | 4.70 | 3.85 | 3.52 | 2.91 | 3.10 | 3.44 | 3.12 | |||||
| Market Cap | 157.04B | 171.97B | 150.84B | 135.40B | 134.53B | 135.11B | 110.69B | 99.63B | 80.78B | 85.20B | 93.34B | 85.57B | |||||
| Enterprise Value | 180.11B | 186.51B | 168.21B | 153.01B | 154.33B | 152.14B | 127.41B | 117.85B | 101.36B | 105.67B | 112.24B | 104.85B | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | 12.94B | 10.23B | 9.46B | 9.16B | 9.37B | 9.84B | 10.31B | 9.43B | 6.90B | 7.90B | 7.42B | 7.85B | |||||
| Net Debt | 23.07B | 14.55B | 17.37B | 17.61B | 19.80B | 17.03B | 16.72B | 18.21B | 20.58B | 20.48B | 18.90B | 19.28B | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| PEG Ratio | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| EV Revenue TTM | |||||||||||||||||
| EV FCF TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
2026-06-15Sale
Owner: Mercier, Johanna
Title: Chief Comm & Corp Aff Officer
Shares: 3,000
Price/Share: $124.27
Value: $372,810.00
Shares Owned: 124,234
Relationship: Officer
Ownership: Direct
2026-06-15Sale
Owner: Dickinson, Andrew D
Title: Chief Financial Officer
Shares: 3,000
Price/Share: $125.40
Value: $376,200.00
Shares Owned: 171,646
Relationship: Officer
Ownership: Direct
2026-06-01Sale
Owner: O'Day, Daniel Patrick
Title: Chairman & CEO
Shares: 15,000
Price/Share: $132.10
Value: $1,981,500.00
Shares Owned: 617,567
Relationship: Director,Officer
Ownership: Direct
2026-05-15Sale
Owner: Mercier, Johanna
Title: Chief Comm & Corp Aff Officer
Shares: 28,000
Price/Share: $131.62
Value: $3,685,360.00
Shares Owned: 125,779
Relationship: Officer
Ownership: Direct
2026-05-15Sale
Owner: Dickinson, Andrew D
Title: Chief Financial Officer
Shares: 3,000
Price/Share: $132.27
Value: $396,810.00
Shares Owned: 173,191
Relationship: Officer
Ownership: Direct
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
No data available for chart
2026-03-31
78.36%
Inst. Shares: 973,233,293
Shares Outstanding: 1,242,000,000
2025-12-31
82.26%
Inst. Shares: 1,023,281,544
Shares Outstanding: 1,244,000,000
2025-09-30
80.21%
Inst. Shares: 996,963,440
Shares Outstanding: 1,243,000,000
2025-06-30
81.16%
Inst. Shares: 1,010,498,017
Shares Outstanding: 1,245,000,000
2025-03-31
78.95%
Inst. Shares: 983,680,226
Shares Outstanding: 1,246,000,000
GILEAD SCIENCES, INC. (GILD) — SEC Financial Statements & Analysis
GILEAD SCIENCES, INC. (GILD) is a biological products, (no diagnostic substances) company, incorporated in DE. GILEAD SCIENCES, INC. trades on Nasdaq as: GILD. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), GILEAD SCIENCES, INC. reported a 5.52% year-over-year revenue growth, a Gross Profit Margin of 79.59% (TTM), a Debt-to-Equity ratio of 0.94x, a Price-to-Sales (P/S) ratio of 5.16x (TTM), a Price-to-Book (P/B) ratio of 13.37x (TTM), at a market cap of $157.04B. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 5.52%
- Gross Profit Margin TTM
- 79.59%
- Debt To Equity
- 0.94x
- P/S TTM
- 5.16x
- P/B TTM
- 13.37x
- Market Cap
- $157.04B
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is GILEAD SCIENCES, INC. in?
GILEAD SCIENCES, INC. (GILD) operates in the Biological Products, (No Diagnostic Substances) industry.
What is GILD's market cap?
GILEAD SCIENCES, INC. (GILD) has a market capitalization of $157.04B as of 2026-06-30.
What exchange does GILD trade on?
GILEAD SCIENCES, INC. (GILD) trades on the Nasdaq.
Where is GILEAD SCIENCES, INC. incorporated?
GILEAD SCIENCES, INC. is incorporated in DE.